Kura Oncology (KURA)
(Delayed Data from NSDQ)
$21.09 USD
+0.31 (1.49%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $21.08 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KURA 21.09 +0.31(1.49%)
Will KURA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KURA
Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
What Makes Kura Oncology (KURA) a New Buy Stock
KURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kura Oncology (KURA) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade
Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?
Other News for KURA
First Week of KURA September 20th Options Trading
7 ‘Death Cross’ Stocks That Could Be Contrarian Buys
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barclays Remains a Buy on Kura Oncology (KURA)
Kura Oncology’s Ziftomenib: A Promising and Potentially Safer Treatment for Type 2 Diabetes